[go: up one dir, main page]

EP2057190A4 - ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE - Google Patents

ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE

Info

Publication number
EP2057190A4
EP2057190A4 EP07840833A EP07840833A EP2057190A4 EP 2057190 A4 EP2057190 A4 EP 2057190A4 EP 07840833 A EP07840833 A EP 07840833A EP 07840833 A EP07840833 A EP 07840833A EP 2057190 A4 EP2057190 A4 EP 2057190A4
Authority
EP
European Patent Office
Prior art keywords
methods
monoclonal antibodies
interferon alpha
alpha monoclonal
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07840833A
Other languages
German (de)
French (fr)
Other versions
EP2057190A2 (en
Inventor
Jacques Banchereau
Kiley Prilliman
Virginia Pascual
Anna Karolina Palucka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of EP2057190A2 publication Critical patent/EP2057190A2/en
Publication of EP2057190A4 publication Critical patent/EP2057190A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07840833A 2006-08-09 2007-08-09 ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE Withdrawn EP2057190A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83659906P 2006-08-09 2006-08-09
PCT/US2007/075616 WO2008021976A2 (en) 2006-08-09 2007-08-09 Anti-interferon alpha monoclonal antibodies and methods for use

Publications (2)

Publication Number Publication Date
EP2057190A2 EP2057190A2 (en) 2009-05-13
EP2057190A4 true EP2057190A4 (en) 2010-07-28

Family

ID=39082973

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07840833A Withdrawn EP2057190A4 (en) 2006-08-09 2007-08-09 ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE

Country Status (3)

Country Link
EP (1) EP2057190A4 (en)
JP (1) JP5230022B2 (en)
WO (1) WO2008021976A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0607490A2 (en) 2005-02-10 2009-09-08 Baylor Res Inst alpha interferon monoclonal antibodies and methods for use
US20100143373A1 (en) * 2006-12-06 2010-06-10 Medimmune, Llc Methods of treating systemic lupus erythematosus
CN101678100A (en) * 2006-12-06 2010-03-24 米迪缪尼有限公司 methods of treating systemic lupus erythematosus
MX2010012052A (en) 2008-05-07 2010-12-14 Novo Nordisk As HUMANIZED ANTIBODIES AGAINST INTERFERON-HUMAN ALPHA.
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN106589122B (en) * 2015-10-20 2020-10-27 中国人民解放军军事医学科学院生物工程研究所 Human anti-human multi-subtype interferon alpha antibody and application thereof
CN112135628B (en) 2018-03-16 2024-11-22 硕腾服务有限责任公司 Peptide vaccine against interleukin 31
EP3765500A2 (en) 2018-03-16 2021-01-20 Zoetis Services LLC Interleukin-31 monoclonal antibodies for veterinary use
RU2737466C1 (en) * 2019-12-30 2020-11-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Humanised neutralizing antibody to human interferon-beta
CN112129952B (en) * 2020-09-21 2023-06-06 普健生物（武汉）科技有限公司 Chemiluminescent kit for detecting human soluble CD14
CN116284368A (en) * 2022-06-15 2023-06-23 重庆艾生斯生物工程有限公司 Anti-human MxA antibodies or antigen-binding portions thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066649A2 (en) * 2001-02-22 2002-08-29 Genentech, Inc. ANTI-INTERFERON-α ANTIBODIES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0607490A2 (en) * 2005-02-10 2009-09-08 Baylor Res Inst alpha interferon monoclonal antibodies and methods for use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066649A2 (en) * 2001-02-22 2002-08-29 Genentech, Inc. ANTI-INTERFERON-α ANTIBODIES

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHANG K C ET AL: "MOLECULAR AND FUNCTIONAL ANALYSIS OF THE VIRUS- AND INTERFERON-INDUCIBLE HUMAN MXA PROMOTER", ARCHIVES OF VIROLOGY, NEW YORK, NY, US, vol. 117, 1991, pages 1 - 15, XP008007812, ISSN: 0304-8608 *
CHUNTHARAPAI ANAN ET AL: "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 15, no. 5, 7 September 2001 (2001-09-07), pages 250 - 260, XP002307361, ISSN: 1043-4666 *
FRAY M D ET AL: "Validation of an Mx/CAT reporter gene assay for the quantification of bovine type-I interferon", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 249, no. 1-2, 1 March 2001 (2001-03-01), pages 235 - 244, XP004317487, ISSN: 0022-1759 *
LITTLE M ET AL: "Of mice and men: hybridoma and recombinant antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 8, 1 August 2000 (2000-08-01), pages 364 - 370, XP004215163, ISSN: 0167-5699 *
OVERALL M L ET AL: "FUNCTIONAL ANALYSIS OF INTERFERON-ALPHA SUBTYPES USING MONOCLONAL ANTIBODIES TO INTERFERON-ALPHA4A-SUBTYPE REACTIVITY, NEUTRALISATION OF BIOLOGICAL ACTIVITIES AND EPITOPE ANALYSIS", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 29, no. 3, 1992, pages 391 - 399, XP009001288, ISSN: 0161-5890 *
RONNI T ET AL: "THE PROXIMAL INTERFERON-STIMULATED RESPONSE ELEMENTS ARE ESSENTIAL FOR INTERFERON RESPONSIVENESS: A PROMOTER ANALYSIS OF THE ANTIVIRAL MXA GENE", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 18, no. 9, September 1998 (1998-09-01), pages 773 - 781, XP008007716, ISSN: 1079-9907 *

Also Published As

Publication number Publication date
JP5230022B2 (en) 2013-07-10
EP2057190A2 (en) 2009-05-13
JP2010500380A (en) 2010-01-07
WO2008021976A3 (en) 2008-11-13
WO2008021976A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
EP2057190A4 (en) ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE
EP2086583A4 (en) FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USE
EP2212432A4 (en) FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USE
EP2373691A4 (en) ANTI-FXI ANTIBODIES AND METHODS OF USE
EP2091975A4 (en) ANTI-EGFR FAMILY ANTIBODIES, BISPECIFIC ANTI-EGFR FAMILY ANTIBODIES AND METHODS OF USE THEREOF
FR20C1033I2 (en) ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS OF USE
EP2057465A4 (en) SPECIFIC ORGAN PROTEINS AND METHODS OF USE
EP2350655A4 (en) METHODS OF USING ANTIBODIES AND THEIR ANALOGUES
EP2427479A4 (en) ANTIBODIES AND METHODS OF USE THEREOF
MA30684B1 (en) ANTI-MN ANTIBODIES AND METHODS OF USE THEREOF
EP1933884A4 (en) IMAGING AGENTS AND METHODS OF USE
EP1940466A4 (en) ANTI-ADDL MONOCLONAL ANTIBODIES AND THEIR USE
EP1915177A4 (en) ALPHA-SYNUCLEIN ANTIBODIES AND RELATED TECHNIQUES
EP2353005A4 (en) METHODS AND COMPOSITIONS FOR THE DETECTION OF ANTIBODIES FIXING THE COMPLEMENT
EP2285462A4 (en) CHROMATOGRAPHY SYSTEMS AND METHODS OF USE
EP2046413A4 (en) MEDICAL SYSTEMS AND METHODS OF USE
EP2236604A4 (en) ANTI-NR10 ANTIBODIES AND USE THEREOF
EP2038252A4 (en) SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF
EP2054049A4 (en) SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF
EP2373679A4 (en) HEPPIDINE MINI PEPTIDES AND METHODS OF USE
EP2117607A4 (en) IMAGING AGENTS AND METHODS OF USE
EP2367570A4 (en) ANTI-IL-6 ANTIBODIES AND USE THEREOF
EP2037737A4 (en) PROTEINS, NUCLEIC ACIDS ENCODING THE SAME, AND THEIR ASSOCIATED METHODS OF USE
EP2170393A4 (en) ANTITHROMBOTIC AGENTS AND METHODS OF USE
EP2084275A4 (en) POLYPEPTIDE LIGANDS TARGETING CARTILAGE AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090303

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100624

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20100618BHEP

Ipc: C07K 16/24 20060101AFI20100618BHEP

17Q First examination report despatched

Effective date: 20110329

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150714